| __timestamp | BioMarin Pharmaceutical Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 3932000000 |
| Thursday, January 1, 2015 | 152008000 | 3909000000 |
| Friday, January 1, 2016 | 209620000 | 4946000000 |
| Sunday, January 1, 2017 | 241786000 | 6066000000 |
| Monday, January 1, 2018 | 315264000 | 6547000000 |
| Tuesday, January 1, 2019 | 359466000 | 8078000000 |
| Wednesday, January 1, 2020 | 524272000 | 11773000000 |
| Friday, January 1, 2021 | 470515000 | 9940000000 |
| Saturday, January 1, 2022 | 483669000 | 10137000000 |
| Sunday, January 1, 2023 | 577065000 | 10693000000 |
| Monday, January 1, 2024 | 580235000 | 11949000000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. This analysis delves into the cost of revenue trends for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outpaced BioMarin in cost of revenue, with figures peaking at approximately $10.7 billion in 2023, a staggering 1,750% higher than BioMarin's $577 million. Notably, Bristol-Myers Squibb's cost of revenue grew by 172% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, BioMarin's cost of revenue increased by 345%, indicating a significant scaling of its operations. This data underscores the differing scales and strategies of these two industry players, offering insights into their operational efficiencies and market strategies. As the pharmaceutical industry evolves, understanding these financial dynamics is crucial for stakeholders and investors alike.
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Novartis AG and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Pfizer Inc. vs Bristol-Myers Squibb Company
Cost Insights: Breaking Down Amgen Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and United Therapeutics Corporation
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Vericel Corporation's Expenses